Safety and Efficacy of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients with ST-segment Elevation Myocardial Infarction and Left Ventricular Dysfunction: A Multicenter Randomized, Double-Blind and Placebo-Controlled Clinical Trial.

Conclusions: Allogeneic cardiac stem cells can be safely administered in STEMI patients with LV dysfunction early after revascularization. Low immunogenicity and absence of immune-mediated events will facilitate adequately powered studies to demonstrate their clinical efficacy in this setting.Clinical Trial Registration: NCT 02439398.
PMID: 29921651 [PubMed - as supplied by publisher]

Source: Circulation Research - June 19, 2018 Category: Cardiology Authors: Fernández-Avilés F, Sanz-Ruiz R, Bogaert J, Casado Plasencia A, Gilaberte I, Belmans A, Fernández-Santos ME, Charron D, Mulet M, Yotti R, Palacios I, Luque M, Sádaba R, San Roman JA, Larman M, Sánchez PL, Sanchis J, Jimenez-Navarro MF, Claus P, Al-Da Tags: Circ Res Source Type: research